Puma Biotechnology Inc - Common Stock (PBYI)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 2, 2026Investment Snapshot
- Trading 3% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 29.1% with 16.3% net margin
Puma Biotechnology Inc - Common Stock (PBYI) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $344 million . Key value metrics: P/E ratio 9.1, P/B ratio 2.64, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Puma Biotechnology Inc - Common Stock — Fundamental Analysis Summary
Puma Biotechnology Inc - Common Stock (PBYI) is currently trading 3% above its Graham Number of $6.56, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 9.1x.
On financial health, PBYI shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 29.1% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.17.
StockPik's composite Value Score for PBYI is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PBYI reports a high gross margin of 72.5% (sector average: 33.5%) and a solid operating margin of 18.1%.
PBYI shows revenue declining at 1% year-over-year, with earnings growing at 3%.